Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201033 | 0.87 | RIPK1 (0.63) | RIPK1RIPK2RIPK3TNFKMT2A | |
| SCHEMBL16201032 | 0.86 | RIPK1 (0.48) | RIPK1RIPK2RIPK3TNFKMT2A | |
| SCHEMBL16084986 | 0.76 | RIPK1 (0.60) | RIPK1RIPK2RIPK3TNF | |
| SCHEMBL16084981 | 0.75 | RIPK1 (0.62) | RIPK1RIPK2RIPK3TNF | |
| SCHEMBL16201035 | 0.73 | RIPK1 (0.62) | RIPK1RIPK2RIPK3TNFKMT2A | |
| SCHEMBL16084982 | 0.73 | RIPK1 (0.55) | RIPK1RIPK2RIPK3TNF | |
| SCHEMBL16084952 | 0.71 | RIPK1 (0.49) | RIPK1RIPK2RIPK3TNFKMT2A | |
| SCHEMBL16084960 | 0.69 | RIPK1 (0.67) | RIPK1RIPK2RIPK3 | |
| SCHEMBL16201023 | 0.68 | RIPK1 (0.49) | RIPK1RIPK2RIPK3 | |
| SCHEMBL860014 | 0.67 | RIPK1 (0.76) | RIPK1TNFKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725452-B2 | Substituted indoles and pyrroles as RIP kinase inhibitors | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885RIPK2 4/4885RIPK3 1/4885 |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885RIPK2 4/4885RIPK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.